ROARABLE
FREE $100K
My Trading Account →
▾
Trading Profile Active
Active Trader
Verified Trader
⚡ My $100K Trading Account → ★ My Saved Watchlist →
🟢 My $100K Account → Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / ALKS
AXSM (35) ABVX (54) AMRX (71) KNSA (71) ⌘ Pro Terminal →

Alkermes plc (ALKS) — RQD Stock Rating Cockpit

$44.89 -0.99% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $44.92

Alkermes plc (ALKS) earns a Roarable Rating of B+ (Buy) with 78/100 RQD Confidence. High-quality cash engine (86.7% gross margin, 14% return on capital) with steady institutional support. The company’s underlying cash engine and institutional positioning keep the composite score in the Green Buy zone.

ROARABLE B+ • BUY Cap $7.61B
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on ALKS Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is ALKS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Alkermes plc (NASDAQ: ALKS) is rated B+ (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 78/100 at a spot price of $44.89 (-0.99% 1D, market cap $7.61B). Pillar breakdown: Fundamental Cash Engine 17/20, Institutional 13F & Options Flow 14/20, SEC Balance-Sheet Forensics 15/20, FRED Macro Regime Fit 16/20, and Executive Insider Alignment 16/20. Across 1015 tracked Health Care issuers, ALKS ranks #22 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does ALKS compare to AXSM and ABVX in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ALKS carries a Roarable B+ (78/100 RQD), trailing P/E of 31.5x, gross margin of 86.7%, and ROIC of 14.0%. By comparison, AXSM (Axsome Therapeutics Inc.) holds a D- grade (35/100 RQD, P/E N/A, ROIC -21.9%, cap $7.57B) and ABVX (Abivax SA) posts a D+ grade (54/100 RQD, P/E 32.8x, ROIC 9.9%, cap $7.56B). Among the 5-stock peer group, ALKS leads on earnings multiple (31.5x) while AMRX leads on capital efficiency (14.1% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for ALKS?
▼

Per ALKS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001520262), Alkermes plc generated $1.48B in revenue (-5.2% YoY), $241.7M in net income, and $480.3M in free cash flow against $2.49B in total assets and $0 in total debt. Key quantitative strengths: Strong cash generator (86.7% gross margin)—profits are backed by real money, not accounting tricks. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $44.92 (+0.06%)🧬 Cannibal Buyback (-2.36% YoY Shares)⚙️ Cash Engine: 17/20 (A-) • 32.5% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record: Scores of 78/100 (B+) historically ranked in the Top 10% of excess returns over the next 90 days (+7.9% avg 90D alpha vs SPY • 70.6% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERBUY • B+
025507510078
3-of-3 Quant Analysts Bullish
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw B+ · Rk B+
Cash (17)Whales (14)SEC (15)Macro (16)CEO (16)
Each axis scored 0–20
12M PRICE TARGET CONE+9% Base Target
$58 Bull$49 Base$37 Bear
📬 FREE ALKS RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ALKS)Realized 20D OHLCV Swing Band: ±6.4%
Deterministic 5-Pillar Attribution (78/100 Composite)
🔍 WHY ALKS SCORES 78/100 (B+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Cash Engine Quality+17/20 pts (22% of score)

SEC XBRL FY 2025 (10-K): 32.5% FCF Margin ($480.3M FCF) & 86.7% Gross Margin

▲ #2 Bullish Driver: Macro Regime Fit+16/20 pts (21% of score)

FRED Regime × Technicals: 62% of 52W Range • RSI-14 at 61 (BULLISH MOMENTUM)

▼ #1 Drag / Risk Factor: Whale & Options Positioning14/20 pts (-6 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-6 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
70
Grade B$39.08+11.3% Next Q
Q2 (-2Q)
73
Grade B$43.48+4.1% Next Q
Q3 (-1Q)
75
Grade B+$45.25-0.8% Next Q
Current
78
Grade B+$44.89+7.9% Hist 90D α
Trajectory: B (70) → B+ (78)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the ALKS Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 78/100 (B+) score, ALKS faces multiple-compression risk if 31.5x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Broader market pullbacks can still drag down strong stocks in the short run.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-2.36% YoY Shares) — any gross margin slip below 84.2% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($43.85) or 200D SMA ($40.68) invalidates the momentum regime and cuts Target Base ($48.93) toward Bear Floor ($36.81).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $ALKS• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “ALKS Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 78%NO 22%Trade / Inspect Odds →
RSI-14 MOMENTUMBULLISH MOMENTUM
6130 Oversold · 70 Hot
ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)
8.03>3.0 Fortress Safe
PIOTROSKI F-SCOREHIGH QUALITY (7–9)
7 / 99-Pt Accounting
52-WEEK LASER RANGE62% OF RANGE
L: $27$44.89H: $56
1. Money & Cash Health● HEALTHY
Are profits real cash in the bank?

Real cash coming in backs up reported profits (86.7% gross margin and healthy balance-sheet cushion).

Factor Grade: A-RQD 17 / 20
2. Big Money & Insiders● BUYING
Are whales & executives buying or selling?

Hedge funds and options traders are leaning bullish, showing strong institutional appetite.

Factor Grade: BRQD 30 / 40
3. Hidden Risks & Market Weather● ALL CLEAR
SEC fine-print scan & interest-rate fit

Clean SEC fine-print check with low hidden accounting risk and favorable interest-rate weather.

Factor Grade: B+RQD 31 / 40
MULTI-MODEL QUANT PANEL DELIBERATION

3-of-3 Quant Analysts Bullish on ALKS

Cash & Moat Bull AI
ROIC & Free Cash Flow Model
BULLISH (85)

14.0% ROIC with 86.7% gross margin and 6.31% FCF yield.

SEC Forensic Auditor AI
10-K Accruals & Altman-Z Guard
BULLISH (75)

Altman-Z 8.03 and Piotroski 7/9 pass balance-sheet audit.

Whale & Macro Hawk AI
Options Skew, 13F & Fed NetLiq
BULLISH (77)

30/40 institutional & smart-money positioning score with 16/20 macro alignment.

Bull Case: Why Buyers Like ALKS
  • ✓Strong cash generator (86.7% gross margin)—profits are backed by real money, not accounting tricks.
  • ✓Company leadership has skin in the game with net positive insider conviction.
  • ✓Clean SEC annual filing review with no major hidden accounting time-bombs.
Bear Case: What Could Go Wrong
  • !Broader market pullbacks can still drag down strong stocks in the short run.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk

Scheduled RQD Strong Buys & Whale Accumulation Briefing (ALKS Tape Review)

  • ✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
  • ✓Forensic Red-Light accounting & dilution traps to review on your watchlist
  • ✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
ALKS // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +31.37%⚡ TESTING RESISTANCE
2026-11-03O $45.37H $45.37L $44.89C $44.89VOL 1.11M
RES: $45.92SUP: $35.11SMA50: $43.85SMA200: $40.68
$57.45$50.07$42.69$35.30$27.92RES $45.92SUP $35.11$44.892026-05-042026-06-182026-08-052026-09-212026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

ALKS Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 ALKS Butterfly Map → + Track ALKS →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
24.3%/yr Implied 5Y Growth

vs. -5.2% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on ALKS today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for ALKS. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for ALKS today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ALKS)

Health Care Rank #22 of 1015 ⚔️ AXSM vs ALKS Full Matrix →

1. Head-to-Head Health Care Peer Comparison (ALKS vs. AXSM, ABVX, AMRX, KNSA)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Alkermes plc (ALKS) ranks #22 by composite RQD confidence (78/100, grade B+) and #126 by equity capitalization ($7.61B). Within this direct 5-issuer industry benchmark cohort, ALKS leads on earnings valuation at 31.5x trailing P/E, while AMRX leads on capital efficiency and profitability with 14.1% ROIC and 36.9% gross margin. ALKS currently leads its immediate peer cohort in composite quantitative strength at 78/100 (B+).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
ALKS ACTIVE
Alkermes plc
B+ 78/100 31.5x 86.7% 14.0% -0.99% $7.61B Benchmark Subject
AXSM
Axsome Therapeutics Inc.
D- 35/100 — — -21.9% -5.83% $7.57B /axsm-vs-alks →
ABVX
Abivax SA
D+ 54/100 32.8x — 9.9% -1.94% $7.56B /abvx-vs-alks →
AMRX
Amneal Pharmaceuticals Inc.
B- 71/100 103.2x 36.9% 14.1% -4.97% $7.49B /amrx-vs-alks →
KNSA
Kiniksa Pharmaceuticals International plc (Class A)
B- 71/100 129.9x 88.5% 9.9% -1.56% $7.25B /knsa-vs-alks →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001520262 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Alkermes plc (ALKS) reported GAAP revenue of $1.48B (-5.2% vs. FY2024 revenue of $1.56B , and -11.3% cumulative change since FY2023) , GAAP net income of $241.7M, operating cash flow of $520.8M, and free cash flow of $480.3M (+18.4% YoY). On the balance sheet, ALKS closed FY2025 with $2.49B in total assets against $0 in total debt (Altman Z-Score: 8.03, Piotroski F-Score: 7/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $1.48B $241.7M $520.8M $480.3M $2.49B $0
FY2024 (FY) 2024-12-31 $1.56B $367.1M $439.1M $405.6M $2.06B $265.8M
FY2023 (FY) 2023-12-31 $1.66B $355.8M $401.4M $326.5M $4.19B $979.6M

3. ALKS Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is ALKS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Alkermes plc (NASDAQ: ALKS) is rated B+ (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 78/100 at a spot price of $44.89 (-0.99% 1D, market cap $7.61B). Pillar breakdown: Fundamental Cash Engine 17/20, Institutional 13F & Options Flow 14/20, SEC Balance-Sheet Forensics 15/20, FRED Macro Regime Fit 16/20, and Executive Insider Alignment 16/20. Across 1015 tracked Health Care issuers, ALKS ranks #22 in composite RQD confidence.

How does ALKS compare to AXSM and ABVX in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ALKS carries a Roarable B+ (78/100 RQD), trailing P/E of 31.5x, gross margin of 86.7%, and ROIC of 14.0%. By comparison, AXSM (Axsome Therapeutics Inc.) holds a D- grade (35/100 RQD, P/E N/A, ROIC -21.9%, cap $7.57B) and ABVX (Abivax SA) posts a D+ grade (54/100 RQD, P/E 32.8x, ROIC 9.9%, cap $7.56B). Among the 5-stock peer group, ALKS leads on earnings multiple (31.5x) while AMRX leads on capital efficiency (14.1% ROIC).

What are the biggest fundamental strengths and SEC risk factors for ALKS?

Per ALKS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001520262), Alkermes plc generated $1.48B in revenue (-5.2% YoY), $241.7M in net income, and $480.3M in free cash flow against $2.49B in total assets and $0 in total debt. Key quantitative strengths: Strong cash generator (86.7% gross margin)—profits are backed by real money, not accounting tricks. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run. Institutional options positioning shows a 50% call / 50% put premium split.

Where is ALKS trading relative to its 50-day, 200-day, and 52-week technical levels?

ALKS last traded at $44.89 (-0.99% on volume of 2,162,831 shares), positioning the stock +2.37% above its 50-day simple moving average ($43.85) and +10.35% above its 200-day simple moving average ($40.68). Across its 52-week range of $27.00 to $55.67, ALKS sits at the 62.4% percentile with a 14-day RSI of 61.0 (BULLISH MOMENTUM) and an implied next-earnings move of ±6.4% ($42.02 to $47.76).

Direct Sub-Reports: ALKS RQD Cockpit ALKS 12M Forecast ALKS Earnings & Move ALKS Dividends & DRIP ALKS Insiders & 13F ALKS Whale Options ALKS Profit Sankey ALKS News & Why
ROARABLE RATING BRIEF • RQD 78/100 (B+) ✓ SEC XBRL & RQD VERIFIED

ALKS — Alkermes plc: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Alkermes plc (ALKS) earns a live Roarable RQD composite score of 78/100, corresponding to a B+ letter grade (Roarable Buy) at a spot price of $44.89 (-0.99% 1D, market capitalization $7.61B).

  • Fundamental Cash Engine (17/20): Anchored by return on invested capital (ROIC) of 14.0%, gross margin of 86.7%, operating margin of 17.2%, and free cash flow yield of 6.31%.
  • Whale 13F & Options Flow (14/20) + Insider Conviction (16/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (16/20) + Forensic Balance Sheet (15/20): Incorporates a 1.05x equity beta, Altman Z-Score of 8.03, Piotroski F-Score of 7/9, and Debt/Equity of 0.00x.

2. Business Model, Unit Margins & SEC Financial Trajectory

Alkermes plc (ALKS) is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Pharmaceutical Preparations industry. Its market capitalization is $7.6B, per the market data. Gross margin of 86.7% per the market data indicates a high-margin revenue base.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Alkermes plc (ALKS) reported $1.48B in annual revenue (up from $1.56B in FY2024, -5.2% YoY) and $241.7M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($1.66B revenue, $355.8M net income) through FY2025, ALKS scaled operating cash flow to $520.8M and free cash flow to $480.3M, backed by $2.49B in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (B+ • RQD 78/100): Strong cash generator (86.7% gross margin)—profits are backed by real money, not accounting tricks. Company leadership has skin in the game with net positive insider conviction. With Fundamental Cash Engine at 17/20 and Institutional Whale Flow at 14/20, sustained execution supports upside toward the upper end of the $27.00 – $55.67 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Broader market pullbacks can still drag down strong stocks in the short run. Investors must weigh 31.5x trailing P/E and 25.1x EV/EBITDA against 17.2% operating margins and a 1.05x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Operating in Biotechnology: Pharmaceutical Preparations (Health Care), ALKS carries a macro regime beta of 1.05 and gross margin of 86.7%.

  • Key Question #1: Can ALKS sustain or expand its 17.2% operating margin and 14.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $1.48B and free cash flow of $480.3M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is ALKS's 29.3x forward P/E multiple to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.05x)?

ALKS Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Alkermes plc (ALKS) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to ALKS Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

ALKS Bull vs. Bear Conversation Board — What's Your Call at $44.89?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON ALKS 🐻 33% BEARISH CONVICTION
1. Pick Your Side on ALKS:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
SI SiliconVal_Bull RQD DEBATE OPENER • Growth & Tech Investor 🐂 BULLISH 🎯 Target: $58.49 (+29.0%)
📌 Pinned Debate

Free cash flow rose to $480.3M in FY 2025 while debt fell to $0.0M, supported by a 14% ROIC and an Altman Z of 8.03.

The street is overcomplicating Alkermes plc (ALKS). Free cash flow rose to $480.3M in FY 2025 while debt fell to $0.0M, supported by a 14% ROIC and an Altman Z of 8.03.. With an RQD score of 78/100 (B+) and Forensic Balance Sheet at 15/20, any positive earnings surprise or guidance raise forces underweight funds to chase above $48.97.

ArenaChamp_24 🐂 BULL

@ForensicBear Fair point on 31.5x trailing P/E, but you're ignoring the forward operating leverage in Biotechnology: Pharmaceutical Preparations. If gross margin (86.7%) holds, EPS grows into the multiple faster than bears think.

FO ForensicBear RQD DEBATE OPENER • 10-K Footnote Auditor 🐻 BEARISH 🎯 Target: $38.99 (-14.0%)
Spot @ $45.34

Revenue declined from $1.66B in FY 2023 to $1.48B in FY 2025 and Q3 earnings are expected to decline, at a trailing P/E of 31.5.

Careful chasing ALKS at $45.34. Revenue declined from $1.66B in FY 2023 to $1.48B in FY 2025 and Q3 earnings are expected to decline, at a trailing P/E of 31.5.. Gross margin is 86.7%, but operating margin is 17.2%, which shows SG&A and reinvestment are eating into bottom-line EPS. Target $38.99 on multiple compression.

LIVE TAPE